Table 2.
Treatment outcome in patients with uncomplicated falciparum infection treated with dihydroartemisinin–piperaquine (DHA/PPQ) or artemether–lumefantrine (AL) in Bosaso and Jowhar sites, Somalia
| Treatment responses | DHA-PP | AL | ||
|---|---|---|---|---|
| Bosaso (N = 92) | Jowhar (N = 108) | Bosaso (N = 88) | Jowhar (N = 51) | |
| Parasitaemia on day 3 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PCR-uncorrected | ||||
| ETF, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LCF, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LPF, n (%) | 2 (2.5) | 3 (2.8) | 0 (0) | 0 (0) |
| ACPR, n (%) | 78 (97.5) | 103 (97.2) | 84 (100) | 51 (100) |
| Total per protocol | 80 | 106 | 84 | 51 |
| Lost/withdrawn, n (%) | 12 (13.0) | 2 (1.9) | 4 (4.5) | 0 (0) |
| Kaplan–Meier: cure rate | 78 (97.5) | 103 (97.2) | 84 (100) | 51 (100) |
| PCR-corrected | ||||
| ETF, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LCF, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LPF, n (%) | NA* | 1 (1.0) | 0 (0) | 0 (0) |
| ACPR, n (%) | NA* | 103 (99.0) | 84 (100) | 51 (100) |
| Total per protocol | NA* | 104 | 84 | 51 |
| Lost/withdrawals/re-infection: n (%) | NA* | 4 (3.7) | 4 (4.5) | 0 (0) |
| Kaplan–Meier: cure rate | NA* | 103 (99.1) | 84 (100) | 51 (100) |
*PCR analysis to differentiate between recrudescence and new infection was not done for the two patients in the DHA/PPQ group in Bosaso because suitable samples were not available at the time of recurrence
ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response